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Abstract
Background: To report on the acute toxicity in children with medulloblastoma undergoing intensity-modulated
radiation therapy (IMRT) with daily intrafractionally modulated junctions.
Methods: Newly diagnosed patients, aged 3–21, with standard-risk (SR) or high-risk (HR) medulloblastoma were
eligible. A dose of 23.4 or 36.0Gy in daily fractions of 1.8Gy was prescribed to the craniospinal axis, followed by a
boost to the primary tumor bed (54 or 55.8Gy) and metastases (39.6–55.8Gy), when indicated. Weekly, an intravenous
bolus of vincristine was combined for patients with SR medulloblastoma and patients participating in the COG-ACNS-
0332 study. Common toxicity criteria (CTC, version 2.0) focusing on skin, alopecia, voice changes, conjunctivitis,
anorexia, dysphagia, gastro-intestinal symptoms, headache, fatigue and hematological changes were scored weekly
during radiotherapy.
Results: From 2010 to 2014, data from 15 consecutive patients (SR, n = 7; HR, n = 8) were collected. Within 72 h from
onset of treatment, vomiting (66 %) and headache (46 %) occurred. During week 3 of treatment, a peak incidence in
constipation (33 %) and abdominal pain/cramping (40 %) was observed, but only in the subgroup of patients (n = 9)
receiving vincristine (constipation: 56 vs 0 %, P = .04; pain/cramping: 67 vs 0 %, P = .03). At week 6, 73 % of the patients
developed faint erythema of the cranial skin with dry desquamation (40 %) or moist desquamation confined to the
skin folds of the auricle (33 %). No reaction of the skin overlying the spinal target volume was observed.
Conclusions: Headache at onset and gastro-intestinal toxicity, especially in patients receiving weekly vincristine, were
the major complaints of patients with medulloblastoma undergoing craniospinal irradiation with IMRT.
Keywords: Craniospinal irradiation, Acute toxicity, IMRT, Medulloblastoma
Background
The technique of craniospinal irradiation (CSI) is indi-
cated for medulloblastoma/PNET-tumors and some
more rare tumors with leptomeningeal spread like germ-
cell tumors, atypical teratoid rhabdoid tumors and epen-
dymoma [1–6]. The most common malignant embryonal
tumor of the central nervous system in childhood is
medulloblastoma [7, 8]. The treatment of medulloblas-
toma usually includes a combination of surgical resec-
tion, radiotherapy and chemotherapy [1, 2]. Currently,
patients are categorized into standard-risk (SR) and high-
risk (HR) groups. High-risk criteria include: positive cere-
brospinal fluid cytology, or leptomeningeal metastasis on
imaging, or residual tumor at primary site >1.5 cm2, or
extra-axial metastases [9]. More recently, patients with
large-cell anaplastic medulloblastoma are added [10].
Today, the technique most commonly used for treating
the craniospinal axis (CSA) is a combination of two lateral
opposed cranial fields, matched to a posterior field to treat
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the spine. This technique results in dose inhomogeneity,
especially at the craniospinal junction and the spinal-
spinal junction if required, depending on the thecal length
[11]. The conventional technique also leads to a significant
dose to structures anterior to the vertebra (thyroid, heart,
lungs, bone marrow, intestine, kidneys) and the skin over-
lying the spine [11, 12].
In order to reduce the dose to organs at risk without
decreasing the target coverage, other techniques for
CSI are developed. CSI with electrons for the spinal
part can be used as an alternative for photons in small
children [13]. Both electron and proton beam radiation
provide substantial sparing of non-target tissues anter-
ior to the vertebra compared with conventional photon
CSI [13–15]. Intensity Modulated Radiation Therapy
(IMRT) results in better target coverage, improved junc-
tion homogeneity and a large gain in healthy tissue spar-
ing [16–18]. In patients undergoing CSI with helical
tomotherapy, junctions-related uncertainties even do not
exist, because only one set-up point is needed during
the whole treatment [19]. Highly-conformal photon
techniques might result in a reduction of acute and late
toxicity. Most data published on acute toxicity during
CSI are retrospective and focus on a limited number of
items [13, 19–22]. Prospective cumulative toxicity data
on nausea, vomiting, headache, skin reactions and in-
fections are available for a subgroup of patients with
medulloblastoma treated with conventional CSI in the
HIT-91 trial [23].
The purpose of this prospective study is to report on
the acute toxicity of patients with medulloblastoma dur-
ing CSI by IMRT.
Methods
Eligibility
Newly diagnosed patients, with medulloblastoma, aged 3
to 21, were eligible for the prospective registration of
acute toxicity during CSI using IMRT with daily intra-
fractionally modulated junctions [18]. Toxicity items
focusing on skin reactions, alopecia, voice changes,
conjunctivitis, anorexia, dysphagia, vomiting, diarrhea,
constipation, abdominal cramping, headache, fatigue
and hematological changes were scored from baseline
until week 10 after onset of radiotherapy, by an experi-
enced pediatric radiation oncologist. The Common
Toxicity Criteria used for this study (CTC, version 2.0)
are provided in Table 1. Patients with SR or HR medul-
loblastoma, who received induction chemotherapy after
surgery and before the onset of radiotherapy or patients
receiving anesthesia during treatment, were excluded
from the current analysis. Approval for the study was
obtained from the Radboud University Medical Centre
research Ethics Committee. Informed consent was ob-
tained before data collection.
IMRT technique
All patients underwent CSI with IMRT in supine pos-
ition. Details of the procedure are described previously
[18]. Briefly, treatment planning, using Pinnacle v.8.0 h
software (Philips Medical Systems, Andover, MA), was
based on a CT-scan obtained with a customized neck
support (AccuForm Custom Cushions, Accuform, MED-
TEC, Orange City, IA), a five-point fixation mask
immobilization for the head (Efficast High- Precision
Mask, Orfit Masks, Orfit Industries NV, Wijnegem,
Belgium) and a cast for body fixation. The clinical target
volume (CTV) was delineated comprising the entire
brain and meninges for the cranial part. The spinal CTV
contained the spinal canal as observed on CT-scan in-
cluding the cerebrospinal fluid extension to the spinal
ganglia. Based on MR-imaging, the inferior limit of the
spinal CTV was defined at the caudal extent of the the-
cal sac. The spinal planning target volume (PTV) in-
cluded an 8-mm margin in the caudal direction and a
5 mm margin in the lateral, anterior and posterior direc-
tions. For the cranial part of the PTV two parallel-
opposed lateral photon fields were used, with segmental
correction for overdose at the frontal and occipital area.
Under- and overdosage of the craniospinal junction was
prevented by including a daily intra-fractional beam dis-
placement over a total length of 3 centimeters into the
planning calculations. For this purpose, a 6-step junction
was created by successively shifting the inferior borders
of the two opposing cranial fields by 0.5 cm. This in-
duced dose inhomogeneity was subsequently compen-
sated by IMRT optimization of the adjacent spinal fields.
The spinal IMRT beam arrangement consisted of five
coplanar photon beams with gantry angles at 250°, 215°,
180°, 145°, and 110°. Subsequent to CSI, patients re-
ceived a boost with IMRT or VMAT (Volumetric Modu-
lated Arc Therapy) to the primary tumor bed. On
indication, additional boosts to spinal and or intracranial
metastases were delivered with IMRT.
Radiation therapy
Radiotherapy was supposed to be initiated within 31 days
following surgical resection. A dose of 23.4Gy or 36.0Gy
in daily fractions of 1.8Gy was prescribed to the CSA for
patients with SR- or HR medulloblastoma, respectively.
Subsequently, a boost dose of 30.6Gy (total dose SR:
54.0Gy) or 19.8Gy (total dose HR: 55.8Gy) in daily frac-
tions of 1.8Gy was planned to the primary tumor site.
Concomitantly patients with HR disease did receive an
additional boost to doses ranging from 39.6–55.8Gy to
the spinal and/or intracranial metastases.
Chemotherapy
Adjuvant chemotherapy, based on the regimen de-
scribed by Packer et al., started 4 weeks after the end
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of radiotherapy [24]. A weekly intravenous bolus of
vincristine (1.5–2.0 mg/m2) was combined with radio-
therapy for patients with SR medulloblastoma and HR
medulloblastoma participating in the COG-ACNS-
0332 trial [10].
Statistics
Statistical analyses were performed with SPSS 21.0.
Descriptive statistics were used to calculate median
values (and 95 % confidence intervals) of patient,
tumor and treatment characteristics. The Chi-square
test and Fisher’s exact test were used to compare tox-
icity outcomes between different groups.
Results and discussion
Patient and treatment characteristics
Between March 2010 and December 2014, data from 19
consecutive patients with newly diagnosed medulloblas-
toma at the Radboud University Medical Centre, were
collected. Four patients were excluded from analysis for
reasons of induction chemotherapy (n = 3) and
anesthesia (n = 1). The baseline patient and treatment
characteristics are listed in Table 2.
The median age of the patient group was 8 years
(range, 4–16 years). Radiation therapy started within
32 days from surgery in 14 of 15 children (median,
31 days; 95%CI: 29–32 days; range, 15–42 days). All chil-
dren completed radiotherapy within 43 days (median,
Table 1 National Cancer Institute Common Toxicity Criteria, version 2.0
Adverse event Grade
0
Grade 1 Grade 2 Grade 3 Grade 4
Skin/radiation
dermatitis
None Faint erythema/dry
desquamation
Moderate to brisk erythema
or patchy desquamation
mostly confined to skin folds
Confluent moist desquamation
≥1.5 cm diameter, not confined
to skin folds, pitting edema
Skin necrosis, ulceration
of full thickness, bleeding
not induced by trauma
or abrasion
Alopecia Normal Mild hair loss Pronounced hair loss - -
Cough Absent Mild, relieve by
non-prescription
medication
Requiring narcotic antitussive Severe cough or coughing
spasms, poorly controlled
or unresponsive to treatment
-
Voice changes
(hoarseness,
loss of voice)
Normal Mild or intermittent
hoarseness
Persistent hoarseness but
able to vocalize, may have
mild to moderate edema
Whispered speech, not able
to vocalize, may have marked
edema
Marked dyspnea/stridor
requiring tracheostomy
or intubation
Conjunctivitis None Ophthalmologic changes
but asymptomatic (pain/
irritation) or without visual
impairment
Symptomatic/interfering
with function but not
interfering with activities
of daily living
Symptomatic/interfering with
activities of daily living
-
Anorexia None Loss of appetite Oral intake significantly
decreased
Requiring IV fluids Requiring feeding tube
or parenteral nutrition
Dysphagia None Mild, can eat regular diet Requiring pureed, soft or
liquid diet
Requiring feeding tube, IV
hydration/alimentation
Complete obstruction,
cannot swallow saliva
Vomiting None 1x/24 h 2-5x/24 h ≥6x/24 h or need for IV fluids Requiring parenteral
nutrition, hemodynamic
collapse, I.C.U.
Diarrhea None Increase ≤4x/24 h 4-6x/24 h or nocturnal
stools
≥7x/24 h or incontinence,
or need for parenteral support
for dehydration
Hemodynamic collapse,
I.C.U.
Constipation None Requiring stool softener
or dietary modification
Requiring laxatives Requiring manual evacuation
or enema
Obstruction or
megacolon
Abdominal pain
or cramping
None Mild; not interfering with
function
Moderate; pain or analgesics,
interfering with function but
not with activities of daily
living
Severe; pain or analgesics
interfering with activities of
daily living
-
Headache None Mild; non interfering with
function
Moderate; pain or analgesics,
interfering with function but
not with activities of daily living
Severe; pain or analgesics
interfering with activities of
daily living
-
Fatigue/malaise None Increased fatigue, not
altering normal activities
Moderate (decrease of
performance status - 20 % in
Lansky or Karnofsky); difficulty
in performing some activities
Severe (decrease of performance
status—40 % in Lansky or
Karnofsky); loss of ability to
perform some activities
Disabling
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42 days; 95%CI: 41–42 days; range, 39–43 days). Radi-
ation therapy was interrupted for 1 day in one patient,
due to lack of compliance. A weekly bolus of vincristine
was given to all children with SR disease (n = 7). Two
out of eight children with HR disease, participating in
the COG-ACNS-0332 trial, received vincristine. Four pa-
tients with HR disease did receive additional boost doses
to spinal and or intracranial metastases.
Overall toxicity profile
Within 72 h from start of treatment, headache and vomit-
ing were observed in 46 and 66 % of children, respectively
(Fig. 1a and b). A peak incidence in constipation (33 %)
was observed during week 3 (Fig. 1c). From the third week
of radiotherapy, 40 % of the children experienced mild
(grade 1) or moderate (grade 2) abdominal pain/cramping
(Fig. 1d). Anorexia was observed during the whole period
of radiation treatment (Fig. 1e).
Pronounced hair loss occurred in all 15 patients from
week 3. At week 6, 73 % of the patients developed faint
erythema of the occipital part of the cranial skin com-
bined with dry desquamation (40 %), or moist desquam-
ation confined to the skin folds of the auricle (33 %)
(Fig. 1f ). Radiation dermatitis of the skin overlying the
spinal target volume was not observed. Conjunctivitis
was not observed and dysphagia (grade 1), cough
(grade 1) and voice changes (grade 1) were limited to
13, 20 and 13 % of all patients, respectively. Severe
diarrhea (grade 3) was recorded in 1 patient, as a result
of a Salmonella infection.
Before start of radiation therapy, 13 % of the patients
received treatment with corticosteroids. To relieve side
effects of treatment, dexamethasone and ondansetron
were prescribed. From week one to six (w1-6) low doses
of dexamethason (range, 0.5–3.0 mg per day) were used
in 60, 47, 53, 33, 40 and 40 % of patients, respectively.
Ondansetron was used by 47 % (w1), 53 % (w2), 53 %
(w3), 47 % (w4), 40 % (w5) and 33 % (w6) of patients.
Without any use of hematopoiesis stimulating factors,
the median value of white blood cells and platelet count
at nadir was 2,2 · 109/L (range: 1,2–3,1; normal: 4,0–10)
and 121 · 109/L (range: 41–177; normal: 150–400),
respectively.
Toxicity profile in relation to medulloblastoma risk
groups
The acute toxicity profile for headache, skin toxicity, an-
orexia, vomiting, constipation and abdominal cramping
in patients with SR vs HR medulloblastoma is illustrated
in Fig. 2. Although none of the toxicity items scored
were significantly different between the SR and HR
group, there was a trend (P = 0.13) towards an increased
incidence of cranial/ear skin toxicity during the fifth
week in the HR group.
Toxicity profile in relation to intravenous vincristine use
A comparison of acute gastro-intestinal toxicity (anorexia,
abdominal pain/cramping, constipation and vomiting) in
patients with (n = 9) and without (n = 6) concomitant
intravenous vincristine is shown in Fig. 3. Anorexia was
observed more frequently in patients receiving vincristine
during weeks 3 to 6. During week 3, constipation and
abdominal pain/cramping occurred more frequently in
the vincristine group (Fig. 3c and d). No significant
difference in incidence of vomiting, skin reaction or
headache was observed between the groups with and
without vincristine.
Table 2 Patient and treatment characteristics
Patient and treatment characteristics
Sex (n)
Male 8
Female 7
Age at diagnosis (years)
Median 8
Range 4–16
Staging (n)
SR 7
HR M0 0
HR M1 4
HR M2 1
HR M3 3
Time between surgery and start RT (days)
Median 31
Range 15–43
95 % CI median 29–32
CSI dose (n)
23.4 Gy/1.8 7
36.0 Gy/1.8 8
Patients receiving cranial/spinal boost (n) 4
Cranial boost 3
Spinal boost 3
Overall treatment time RT (days)
Median 42
Range 39–43
95 % CI median 41–42
Patients with treatment interruptions (n) 1
Treatment interruptions (days) 1
Chemotherapy (n)
SR (Concomitant and Adjuvant) 7
HR (Concomitant and Adjuvant) 2
HR (Adjuvant only) 6
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Discussion
Gastro-intestinal toxicity was the major complaint during
radiotherapy in children with medulloblastoma under-
going CSI with IMRT. Subgroup analysis revealed the
use of intravenous vincristine as main reason for
gastro-intestinal toxicity. Headache and vomiting were
observed at the onset of treatment.
Within 72 h from the start of treatment, headache and
vomiting were reported in a large number of patients. In
a retrospective study of Suneja et al. headache was ob-
served during radiation treatment in 50 % of children
with mainly medulloblastoma treated by proton beam
therapy to the CSA [22]. Incidence peaked during the
first 2 weeks of the treatment course [22]. The incidence
of nausea and vomiting was 50 and 25 %, respectively
[22]. In a group of 14 patients with medulloblastoma
undergoing CSI by 3D conformal- and tomotherapy in
combination with vincristine (N = 12/14), Huang et al.
observed nausea/vomiting during the course of treat-
ment in 64 % of patients [21]. The combination of head-
ache and vomiting at the onset of radiotherapy in
patients treated with photons and protons, does suggest
that cerebral edema resulting in increased intracranial
pressure, was the main reason for these symptoms [25].
Fig. 1 Toxicity, scored from baseline (w0) until week 10 after onset of radiotherapy, in patients with standard-risk and high-risk medulloblastoma
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In order to reduce headache and vomiting, patients are
given paracetamol, anti-emetics, dexamethasone or a
combination of both [26]. Before start of radiation ther-
apy, 13 % of patients were dependent of steroids. During
the first week of radiotherapy, 60 % of the children needed
dexamethasone to relieve symptoms. According to a
double-blinded placebo-controlled randomized trial by
Wong et al., the addition of dexamethasone to
ondansetron as prophylaxis for radiation induced emesis
from radiotherapy to the upper abdomen, resulted into a
significant improvement of complete control of emesis
during the first 2 weeks of fractionated radiotherapy [27].
Constipation and abdominal pain were only observed
in patients receiving vincristine combined with radio-
therapy and mostly from the third week of treatment.
Anorexia was observed during the whole period of
Fig. 2 Toxicity, scored from baseline (w0) until week 10 after onset of radiotherapy, in patients with standard-risk (SR) versus high-risk (HR)
medulloblastoma. No significant differences were observed between the two groups
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radiation treatment. However, from week 3 it was ob-
served only in the group of patients receiving combined
treatment. Suneja et al. demonstrated anorexia during
the course of treatment in 83 % of patients treated with
proton beam therapy to the CSA [22]. Although signifi-
cant higher radiotherapy doses were delivered to the
CSA in patients with HR compared to SR medulloblas-
toma, there were no significant differences observed in
anorexia, constipation and abdominal cramping. In con-
trast, almost 80 % (versus 0 %) of patients receiving vin-
cristine developed a combination of these symptoms.
Acute gastro-intestinal toxicity during radiotherapy was
mainly related to the concomitant use of vincristine and
independent of the radiotherapy dose. Neurotoxicity of
the gastro-intestinal tract, resulting in constipation and/
or abdominal pain, is a well-known side-effect of vincris-
tine [28]. These symptoms are most prominent approxi-
mately 3 to 10 days after drug administration and
usually resolve within several days after discontinuation
of chemotherapy. The impaired motility of the intestines
is dose related and most prominent if doses larger than
2.0 mg/m2 per bolus are used [28]. In the current ana-
lysis, vincristine related side-effects as constipation and
abdominal pain were mainly observed from the third
week of radiation treatment. Optimization of supportive
care with laxatives can probably explain the decrease in
abdominal pain/cramping from week 4. Neurotoxicity
can be enhanced by the concomitant use of anti-
emetics, such as ondansetron and granisetron [29]. From
the second week of radiotherapy, 54 % of the children
received one or a combination of these medications to
relieve gastro-intestinal symptoms. Randomized con-
trolled trials concerning prevention and/or management
of chemotherapy-induced constipation in oncology pa-
tients are absent.
In line with Suneja et al. alopecia occurred in all pa-
tients from week 3 of treatment [22]. At week 6, 73 % of
patients developed faint erythema of the occipital area of
the cranial skin. In some of them, erythema was com-
bined with dry desquamation (40 %), or patchy des-
quamation confined to the skin folds of the auricle
(33 %). A trend towards more skin toxicity was observed
in patients with HR medulloblastoma. In contrast, radi-
ation dermatitis of the skin overlying the spinal target
volume was not observed. Kortmann et al. reported a
comparable incidence of mild or marked erythema
Fig. 3 Toxicity, scored from baseline (w0) until week 10 after onset of radiotherapy, in patients well (+) or not (−) receiving concomitant
intravenous vincristine. Statistically significant changes (p < 0.05) are indicated by *
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(±75 %) in children with SR and HR medulloblastoma
treated with a conventional CSI technique, without any
significant difference between patients receiving neoad-
juvant or concomitant chemotherapy [23]. According to
Suneja et al., 100 % of the patients receiving proton CSI
developed grade 1 or 2 dermatitis (CTC, version 2.0)
[22]. A benefit in radiation dermatitis in favor of pho-
tons compared to protons can be expected. An explan-
ation for the lack of radiation dermatitis overlying the
spinal skin observed in patients from the current ana-
lysis can be explained by the 5-beam arrangement with
photons significantly reducing the dose close to the skin
[18]. For the cranial part, with a target volume close to
the skin, also a higher entrance dose is expected from
proton beams compared to photon beams [14, 30]. Hair
loss may be permanent with total doses greater than
40 Gy [31].
Overall treatment time is a prognostic factor for
progression-free survival in patients with medulloblas-
toma [32, 33]. All our patients completed radiotherapy
within 43 days. Due to poor compliance one patient re-
sumed treatment after 1 day. Chang et al. reported inter-
ruptions of more than 3 days in 5 % of children treated
with electrons or photons [13]. In the multicenter HIT-
91 trial, Kortmann et al. observed interruptions of
radiotherapy in 33 % of patients receiving induction
chemotherapy compared to 19 % of patients in the main-
tenance chemotherapy arm [23]. This corresponded to a
mean protraction of overall treatment time of 11.5 and
7.5 days, respectively. The main reasons for a different
number of treatment interruptions observed in literature
may be multifactorial: myelosuppression due to chemo-
therapy before radiotherapy, bone marrow sparing radio-
therapy techniques, multicenter versus single center
studies, the use of different hematological criteria for
treatment interruption, and the quality of supportive care.
Although not an objective of this study, late toxicity
remains a major issue after treatment for medulloblas-
toma. Secondary malignancy is one of the endpoints that
needs attention when using highly-conformal photon
techniques with larger areas of low-dose irradiation
compared to the conventional techniques. Recently, the
10-year follow-up data on second malignancy after a
combination of conventional radiotherapy and chemo-
therapy for 379 patients with non-disseminated medullo-
blastoma were published [34]. Interestingly, the majority
of these second malignancies (at least 11 of 15) devel-
oped within the target volume of the craniospinal axis
(N = 7), hematopoietic tissues (N = 3) or bone (N = 1)
and will not be altered by treatment technique.
Conclusion
Headache and vomiting at onset, and gastro-intestinal
toxicity during treatment were the major complaints in
children with medulloblastoma undergoing CSI with
IMRT. Subgroup analysis revealed the use of intravenous
vincristine as main reason for gastro-intestinal toxicity.
In an attempt to compare data from literature, the ma-
jority of items scored during radiotherapy seem to be in-
dependent of treatment technique used. Compared to
protons, electrons and conventional techniques with
photons, a benefit in favor of IMRT is observed for skin
toxicity, especially for the spinal part.
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